Adverse Effect of Intravenous Anesthetics, Sequela, Complication of Anesthesia, Drug Delivery System Malfunction, General Anesthetic Drug Overdose, Hemodynamic Instability, Underdosing of Other General Anesthetics
Conditions
Keywords
closed loop, remifentanil, propofol
Brief summary
Evaluate the feasibility and quality of automated anesthesia, analgesia and fluid management based on a combination of several physiological variables (bispectral index \[BIS\], stroke volume \[SV\], and stroke volume variation \[SVV\]) using 2 independent physiologic closed-loop systems (PCLS) in patients undergoing high risk vascular surgery
Detailed description
Evaluate the feasibility and quality of automated anesthesia, analgesia and fluid management based on a combination of several physiological variables (bispectral index \[BIS\], stroke volume \[SV\], and stroke volume variation \[SVV\]) using 2 independent physiologic closed-loop systems (PCLS) in patients undergoing high risk vascular surgery. All patients will receive total intravenous anesthesia in target controlled infusion mode using the population pharmacokinetic sets of Schnider for propofol and Minto for remifentanil to target the effect-site concentration. Infusion Toolbox 95 version 4.11 software (Free University of Brussels, Brussels, Belgium) implemented in a personal computer serving as a platform for: calculating effect-site concentrations of propofol and remifentanil; displaying effect-site concentration estimates in real time; providing a user interface that permits entry of patients' demographic data (sex, age, weight, and height) and modifications to target concentrations; controlling the propofol and remifentanil infusion pumps (Alaris Medical, Hampshire, United Kingdom); and recording calculated effect-site drug concentrations. All patients will receive a baseline crystalloid infusion (PlasmaLyte, Baxter, Belgium) delivered by a pump at a rate of 3 mL/ kg/h (Fresenius Kabi, Belgium). Additional fluid was given using a goal-directed fluid therapy protocol guided by the cardiac output monitor (EV-1000; Edwards Lifesciences) and consisted of 100 mL boluses (Voluven, Fresenius Kabi, Germany) delivered by our PCLS (Learning Intravenous Resuscitator \[LIR\]). For fluid output, a Q-Core Sapphire Multi-Therapy Infusion Pump (Q-Core, Israel) was controlled by the LIR using software provided by Q-Core via a serial connection (Commands Server R.01). If hypotension occurred (defined as mean arterial pressure \<20% of baseline blood pressure) and no fluid is delivered by the LIR, it will be treated by the anesthesiologist using a vasopressor drug. In this pilot study, each closed loop also will operate independently, guided only by its own respective inputs (BIS for the propofol; SV and SVV for the fluid boluses). The investigators will also measure analgesia using the PhysioDoloris monitoring device (MDoloris Medical Systems, Lille, France).
Interventions
OTHERBIS XP, Covidien, Ireland
Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
OTHEREV-1000 TM, Edwards Lifesciences, Irvine, California, USA
Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
Sponsors
Hopital Foch
Erasme University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* patients scheduled for high risk vascular surgery * Patients American Society Anesthesiologist classification: 3 or 4
Exclusion criteria
* age less than 18 years, * patients with arrhythmias like atrial fibrillation * allergy to latex, propofol, remifentanil, morphine, muscle relaxant or any of the excipients, * pregnant woman * combined general and regional anesthesia,
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of adequate anesthesia defined as a BIS between between 40 and 60, a SVV < 13% and/or cardiac index > 2.5 litre/min/m² for more/equal of 85% of the surgical time | at time of surgery |
Secondary
| Measure | Time frame |
|---|---|
| Drug consumption: propofol dose | at time of surgery |
| amount of fluid given | at time of surgery |
| number of automatic modifications of the propofol and remifentanil concentrations | at time of surgery |
| number of patients movements | at time of surgery |
| number of hemodynamic abnormalities requiring treatment | at time of surgery |
| Drug consumption: remifentanil dose | at time of surgery |
| intraoperative awareness | postoperative day 1 or 2 |
| Occurrence of burst suppression | at time of surgery |
| Need for anesthetist interventions over the system during the surgery | at time of surgery |
| performance of the closed-loop system | at time of surgery |
| Interactions between both closed-loop system during the intraoperative period especially during hypotension episodes | at time of surgery |
| time to tracheal extubation | at time of surgery |
Countries
Belgium
Outcome results
None listed